DeepMed Research

Butantan Institute

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine

Completed

Conditions: Influenza

Interventions: Biological: Butantan Fragmented Inactivated Trivalent Influenza Vaccine

First Posted Date: 2016-06-30

Last Posted Date: 2016-06-30

Lead Sponsor: Butantan Institute

Target Recruit Count: 63

Registration Number: NCT02819115

Locations: 🇧🇷
Centro de Pesquisas Clínicas do Instituto da Criança do Hospital das Clínicas, Sao Paulo, SP, Brazil
🇧🇷
Centro de Referência de Imunobiológicos Especiais (CRIE) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP, Brazil

Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB

Completed

Conditions: Influenza

Interventions: Biological: Butantan Influenza Trivalent, Fragmented and Inactivated vaccine

First Posted Date: 2016-06-30

Last Posted Date: 2016-06-30

Lead Sponsor: Butantan Institute

Target Recruit Count: 120

Registration Number: NCT02819180

Locations: 🇧🇷
Centro de Referência de Imunobiológicos Especiais (CRIE) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Phase 3

Active, not recruiting

Conditions: Dengue

Interventions: Other: Placebo
Biological: Dengue 1,2,3,4 (attenuated) vaccine

First Posted Date: 2015-04-02

Last Posted Date: 2024-02-15

Lead Sponsor: Butantan Institute

Target Recruit Count: 16935

Registration Number: NCT02406729

Locations: 🇧🇷
Instituto de Infectologia Evandro Chagas - Fiocruz, Rio De Janeiro, Brazil
🇧🇷
Faculdade de Medicina de São José do Rio Preto - FAMERP, São José Do Rio Preto, São Paulo, Brazil
🇧🇷
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil

and more 14 locations

Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly

Completed

Conditions: Influenza

Interventions: Biological: Butantan Fragmented Inactivated Trivalent Influenza Vaccine

First Posted Date: 2014-12-10

Last Posted Date: 2015-07-21

Lead Sponsor: Butantan Institute

Target Recruit Count: 120

Registration Number: NCT02313740

Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients

Phase 4

Completed

Conditions: Human Influenza

Interventions: Biological: Trivalent influenza vaccine (inactivated and fragmented).

First Posted Date: 2014-04-04

Last Posted Date: 2015-07-21

Lead Sponsor: Butantan Institute

Target Recruit Count: 195

Registration Number: NCT02104869

Locations: 🇧🇷
Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - Divisão de Clínica Urológica e Divisão de Moléstias Infecciosas, São Paulo, Brazil

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Phase 2

Conditions: Dengue

Interventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine
Other: Placebo
Biological: TetraVax-DV Vaccine - Admixture TV003

First Posted Date: 2012-10-01

Last Posted Date: 2019-01-16

Lead Sponsor: Butantan Institute

Target Recruit Count: 300

Registration Number: NCT01696422

Locations: 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
🇧🇷
Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza

Phase 4

Completed

Conditions: Influenza
Acute Respiratory Infection

Interventions: Biological: Control vaccine
Biological: Influenza vaccine

First Posted Date: 2012-09-26

Last Posted Date: 2023-04-04

Lead Sponsor: Butantan Institute

Target Recruit Count: 1742

Registration Number: NCT01693380

Locations: 🇧🇷
Butantan Institute, Sao Paulo, Brazil

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Completed

Conditions: Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
Safety of Pandemic Influenza A (H1N1)Vaccine
Immunocompromised Patients

Interventions: Biological: Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS

First Posted Date: 2010-10-11

Last Posted Date: 2013-02-06

Lead Sponsor: Butantan Institute

Target Recruit Count: 1152

Registration Number: NCT01218685

Locations: 🇧🇷
Avenida Vital Brasil 1500, Sao Paulo, Brazil

Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: pandemic vaccine 1
Biological: pandemic vaccine 2
Biological: pandemic vaccine 5
Biological: pandemic vaccine 6
Biological: pandemic vaccine 9
Biological: pandemic vaccine 10
Biological: pandmeic vaccine 11
Biological: pandmeic vaccine 12
Biological: pandmic vaccine 13
Biological: placebo group 14

First Posted Date: 2010-04-28

Last Posted Date: 2013-02-06

Lead Sponsor: Butantan Institute

Target Recruit Count: 266

Registration Number: NCT01111968

Locations: 🇧🇷
Centro de Pesquisa Clínica do Hospital Universitário da USP, Sao Paulo, Brazil
🇧🇷
Centro de Pesquisa Clinica do Instituto da Criança do hospital das Clinicas da Faculdade de Medicina da USP, Sao Paulo, Brazil

Rotavirus Vaccine Produced by Butantan Institute

Phase 1

Completed

Conditions: Rotavirus Infections

Interventions: Biological: rotavirus vaccine
Biological: placebo

First Posted Date: 2009-09-22

Last Posted Date: 2013-04-25

Lead Sponsor: Butantan Institute

Target Recruit Count: 80

Registration Number: NCT00981669

Locations: 🇧🇷
Instituto da Criança do Hospital das Clinicas da Faculade de Medicina da USP, Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy